Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 87.5%

Neg 87.5% Neu 0% Pos 0%

Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.